Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study | Zendy

Marco Colleoni | Zendy; Anita GiobbieHurder | Zendy; Meredith M. Regan | Zendy; Beat Thürlimann | Zendy; Henning T. Mouridsen | Zendy; L. Mauriac | Zendy; John Forbes | Zendy; Robert Paridaens | Zendy; István Láng | Zendy; Ian Smith | Zendy; Jacquie Chirgwin | Zendy; Tadeusz Pieńkowski | Zendy; Andrew Wardley | Zendy; Karen N. Price | Zendy; Richard D. Gelber | Zendy; Alan S. Coates | Zendy; Aron Goldhirsch | Zendy

Open Access

Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

Author(s) -

Marco Colleoni,

Anita GiobbieHurder,

Meredith M. Regan,

Beat Thürlimann,

Henning T. Mouridsen,

L. Mauriac,

John Forbes,

Robert Paridaens,

István Láng,

Ian Smith,

Jacquie Chirgwin,

Tadeusz Pieńkowski,

Andrew Wardley,

Karen N. Price,

Richard D. Gelber,

Alan S. Coates,

Aron Goldhirsch

Publication year - 2011

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2010.31.6455

Subject(s) - medicine , letrozole , adjuvant , tamoxifen , oncology , crossover study , breast cancer , cancer , placebo , alternative medicine , pathology

Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR). We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research